Health Care & Life Sciences » Biotechnology | Critical Outcome Technologies Inc.

Critical Outcome Technologies Inc. | Balance Sheet

Fiscal year is May-April. All values CAD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
169.30
830.30
1,865.70
4,729.90
2,008.80
40.70
Total Accounts Receivable
175.90
149.80
170.40
154.70
185.80
65.40
Other Current Assets
86.50
79.70
90.60
546.80
524.90
386.40
Total Current Assets
431.80
1,059.70
2,126.80
5,431.40
2,719.50
492.50
Net Property, Plant & Equipment
47.40
38.10
42.30
54.60
42.50
11.70
Intangible Assets
1,777.40
1,429.90
1,324.10
1,377.20
1,264.70
1,028.20
Total Assets
2,256.70
2,527.70
3,493.20
6,863.30
4,026.70
1,532.40
ST Debt & Current Portion LT Debt
-
346.70
-
-
-
Accounts Payable
377.40
683.90
-
-
-
Other Current Liabilities
1.10
0.00
1,956.20
2,952.40
3,206.20
Total Current Liabilities
378.50
1,030.60
1,956.20
2,952.40
3,206.20
Other Liabilities
-
-
-
-
225.00
Total Liabilities
378.50
1,030.60
1,956.20
2,952.40
3,431.20
Common Equity (Total)
1,878.10
1,497.10
1,537.00
3,910.90
595.50
Total Shareholders' Equity
1,878.10
1,497.10
1,537.00
3,910.90
595.50
Total Equity
1,878.10
1,497.10
1,537.00
3,910.90
595.50
Liabilities & Shareholders' Equity
2,256.70
2,527.70
3,493.20
6,863.30
4,026.70

About Critical Outcome Technologies

View Profile
Address
Canadian Venture Building
Toronto Ontario M5C 1P1
Canada
Employees -
Website http://cotingapharma.com
Updated 07/08/2019
Cotinga Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of cancer and other unmet medical needs. Its lead product candidate, COTI-2, treats ovarian and other gynecological cancers and restores normal cell signaling in cancer with p53 mutations. The company was founded on October 13, 2006 and is headquartered in London, Canada.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.